Turnstone Biologics Corp. reported earnings results for the fourth quarter and full year ended December 31, 2023. For the fourth quarter, the company reported net loss was USD 16.45 million compared to USD 13.67 million a year ago. Basic loss per share from continuing operations was USD 0.73 compared to USD 5.51 a year ago.
For the full year, net loss was USD 55.2 million compared to USD 30.83 million a year ago. Basic loss per share from continuing operations was USD 4.78 compared to USD 12.49 a year ago.